Conjugation of Y. pestis F1-antigen to gold nanoparticles improves immunogenicity

Gregory, Anthony E.; Williamson, E. Diane; Prior, Joann L.; Butcher, Wendy; Thompson, Iain J.; Shaw, Andrew M.; Titball, Richard W.

doi:10.1016/j.vaccine.2012.09.021

Cited by 58 publications

(38 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Compared with mice vaccinated with AuNP-F1 in PBS or unconjugated F1-antigen in PBS or alhydrogel, mice vaccinated with AuNP-F1 in alhydrogel generated the highest IgG antibody response to F1-antigen [224]. …”

Section: Other Vaccines For Plaguementioning

confidence: 99%

Plague Vaccines: Status and Future

Sun

2016

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Three major plague pandemics caused by the gram-negative bacterium Yersinia pestis have killed nearly 200 million people in human history. Due to its extreme virulence and the ease of its transmission, Y. pestis has been used purposefully for biowarfare in the past. Currently, plague epidemics are still breaking out sporadically in most of parts of the world, including the United States. Approximately 2000 cases of plague are reported each year to the World Health Organization. However, the potential use of the bacteria in modern times as an agent of bioterrorism and the emergence of a Y. pestis strain resistant to eight antibiotics bring out severe public health concerns. Therefore, prophylactic vaccination against this disease holds the brightest prospect for its long-term prevention. Here, we summarize the progress of the current vaccine development for counteracting plague.

show abstract

Section: Other Vaccines For Plaguementioning

confidence: 99%

Plague Vaccines: Status and Future

Sun

2016

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

show abstract

“…38 A recent study on F1-loaded PLGA/PEG microspheres showed that a single vaccine dose was sufficient to protect mice from challenge. 39 Nanoparticle delivery systems composed of poly(anhydride), 41, 42 gold, 43 lipoproteins, 44 or a hybrid of lipids and biopolymers 23 have been developed for plague vaccines. A single intranasal dose of recombinant F1-V-loaded poly(anhydride) nanoparticles led to prolonged lung disposition 41 and generated high levels of antigen-specific antibody responses, 42 with the overall kinetics dictated by the chemical composition, hydrophobicity, and degradation rate of poly(anhydride) particles.…”

Section: Particulate Vaccines Against Category a Bioterrorism Agentsmentioning

confidence: 99%

Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens

Fan

Moon

2016

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Bioterrorism agents that can be easily transmitted with high mortality rates and cause debilitating diseases pose major threats to national security and public health. The recent Ebola virus outbreak in West Africa and ongoing Zika virus outbreak in Brazil, now spreading throughout Latin America, are case examples of emerging infectious pathogens that have incited widespread fear and economic and social disruption on a global scale. Prophylactic vaccines would provide effective countermeasures against infectious pathogens and biological warfare agents. However, traditional approaches relying on attenuated or inactivated vaccines have been hampered by their unacceptable levels of reactogenicity and safety issues, whereas subunit antigen-based vaccines suffer from suboptimal immunogenicity and efficacy. In contrast, particulate vaccine delivery systems offer key advantages, including efficient and stable delivery of subunit antigens, co-delivery of adjuvant molecules to bolster immune responses, low reactogenicity due to the use of biocompatible biomaterials, and robust efficiency to elicit humoral and cellular immunity in systemic and mucosal tissues. Thus, vaccine nanoparticles and microparticles are promising platforms for clinical development of biodefense vaccines. In this review, we summarize the current status of research efforts to develop particulate vaccine delivery systems against bioterrorism agents and emerging infectious pathogens.

show abstract

“…They found that the conjugate produced higher titers of anti‐NgR antibody than that with Freund's adjuvant, and improved the repair of spinal cord‐injured rats . Yersinia pestis F1‐antigen coated on the surface of 15 nm AuNPs generated a greater IgG antibody response in mice compared to F1‐antigen alone …”

Section: Gold Nanomaterialsmentioning

confidence: 99%

Functional Nanomaterials Can Optimize the Efficacy of Vaccines

Liu

Tian

et al. 2014

Small

View full text Add to dashboard Cite

Nanoscale materials can improve the efficacy of vaccines. Herein we review latest developments that use nanomaterials for vaccines. By highlighting the relationships between the nanoscale physicochemical characteristics and working mechanisms of nanomaterials, this paper shows the current status of the developments where researchers employ functional nanomaterials as vector and/or immunoregulators for vaccines. It also provides us some clues for improving the design and application of nanomaterials to optimize the efficacy of vaccines.

show abstract

Conjugation of Y. pestis F1-antigen to gold nanoparticles improves immunogenicity

Cited by 58 publications

References 50 publications

Plague Vaccines: Status and Future

Plague Vaccines: Status and Future

Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens

Functional Nanomaterials Can Optimize the Efficacy of Vaccines

Contact Info

Product

Resources

About